Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT-CAR-NK in Advanced Solid Tumors
NCT07410494Phase 2Recruiting
- Sponsor
- Essen BioTech
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of EB-SELECT Single-Target CAR-NK Cells and EB-SELECT Dual-Target CAR-NK Cells in solid tumor, breast cancer, non-small cell lung cancer (NSCLC) and 7 more (2 arms), sponsored by Essen BioTech. Primary endpoints: Adverse Events at 28 days and Dose-Limiting Toxicities at 28 days. Started Feb 2026; status: recruiting.
02
Drugs
EB-SELECT Single-Target CAR-NK CellsEB-SELECT Dual-Target CAR-NK Cells
03
Conditions
solid tumorbreast cancernon-small cell lung cancer (NSCLC)colorectal cancer (CRC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07410494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07410494.